Current research has found that VCAN is closely related to the expression of immune checkpoint genes and tumour mutation burden, and it may be a biomarker for the sensitivity of immune checkpoint (PD-1/CTLA-4) inhibitors 11. The gene discussed is VCAN; the disease is neoplasm.